Compare Aurora Cannabis Inc (ACB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aurora Cannabis Inc vs Zoetis Inc — how do they compare? Aurora Cannabis Inc trades at $3.8 (market cap $223.59M), while Zoetis Inc trades at $73.32 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 139.3× Aurora Cannabis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | ZTS | |
|---|---|---|
Market Cap | $223.59M | $31.14B |
Sector | Health | Health |
52-Week High | $6.23 | $156.76 |
52-Week Low | $2.58 | $71.91 |
Enterprise Value | $168.09M | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $3.79, up 31.14% amid a hostile takeover bid from Curaleaf at $4 per share. The stock shows neutral technical signals with bearish moving averages. Fundamentally, 2025 revenue grew to $343.29M with a slim net profit of $1.59M, but 2026 projections indicate a net loss of $120M. Analyst consensus is mixed with 21.43% buy ratings, reflecting uncertainty over the acquisition offer and standalone prospects.
The outlook hinges on the takeover outcome; acceptance could provide immediate upside, while rejection may pressure shares given weak 2026 forecasts. Key risks include execution challenges, regulatory hurdles, and competitive pressures. Investors face a binary event driving near-term volatility.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
